Loading...
Short-course oral direct-acting antiviral agents result in virological cure for most patients with chronic hepatitis C (CHC) regardless of age, presence of cirrhosis, and other comorbidities. In this retrospective cohort study, researchers used a large nationwide clinical database and evaluated whether direct-acting antiviral treatment (without interferon) is associated with lower risks for liver-related and nonliver-related morbidity and death in patients with CHC.
A total of 246,000 patients with CHC (mean age, 59) were included in the study; of these, 205,000 were untreated and 41,000 received ≥1 prescriptions for direct-acting antiviral medications without interferon. Adjusted for numerous variables, direct-acting antiviral treatment was…